MSI-H/dMMR

News alerts, weekly reports and conference planners

Related biomarkers:

Expression

Mutation

Others

‹

›

MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) regorafenib Sensitive : C2 ASCO-GI 2023 - 2wk	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks regorafenib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval J Clin Oncol - 3 weeks (New C3) pembrolizumab Sensitive : A1 J Clin Oncol - 3wk	pembrolizumab Sensitive: A1 - Approval J Clin Oncol - 3 weeks pembrolizumab Sensitive : A1 J Clin Oncol - 3 weeks - (New C3)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Peritoneal Cancer	MSI-H/dMMR	Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Fallopian Tube Cancer	MSI-H/dMMR	Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Maxillary Sinus Carcinoma	MSI-H/dMMR	Maxillary Sinus Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Penile Cancer	MSI-H/dMMR	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Ovarian Cancer	MSI-H/dMMR	Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Germ Cell Tumors	MSI-H/dMMR	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Neuroendocrine Tumor	MSI-H/dMMR	Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Pancreatic Adenocarcinoma	MSI-H/dMMR	Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Cervical Cancer	MSI-H/dMMR	Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Chordoma	MSI-H/dMMR	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2

MSI-H/dMMR

Associations